


# Stabilis



## Furosemide



Nombre comercial

|            |                                                                                                                                                                                                            |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Demistec   | México                                                                                                                                                                                                     |
| Desal      | Turquía                                                                                                                                                                                                    |
| Diorin     | Colombia                                                                                                                                                                                                   |
| Diurefur   | Marruecos                                                                                                                                                                                                  |
| Diusemid   | Arabia Saudita                                                                                                                                                                                             |
| Edemid     | Croacia, Eslovenia, Venezuela                                                                                                                                                                              |
| Frusemide  | Malasia, Nueva Zelanda                                                                                                                                                                                     |
| Frusix     | Venezuela                                                                                                                                                                                                  |
| Furilan    | Marruecos, Túnez                                                                                                                                                                                           |
| Furix      | Islandia, Noruega, Suecia                                                                                                                                                                                  |
| Furodiurol | México                                                                                                                                                                                                     |
| Furomid    | Turquía                                                                                                                                                                                                    |
| Furon      | Austria, Hungría                                                                                                                                                                                           |
| Furophax   | Marruecos                                                                                                                                                                                                  |
| Furorese   | Alemania, Luxemburgo                                                                                                                                                                                       |
| Furosan    | Brasil                                                                                                                                                                                                     |
| Furosemid  | Alemania                                                                                                                                                                                                   |
| Furoxem    | Túnez                                                                                                                                                                                                      |
| Fursemid   | Alemania                                                                                                                                                                                                   |
| Hydroflux  | Grecia                                                                                                                                                                                                     |
| Impugan    | Arabia Saudita                                                                                                                                                                                             |
| Kolkin     | Argentina                                                                                                                                                                                                  |
| Lasilix    | Estados Unidos de América, Francia, Japón, Marruecos, Polonia, Túnez                                                                                                                                       |
| Lasiphar   | Egipto                                                                                                                                                                                                     |
| Lasix      | Alemania, Arabia Saudita, Argentina, Australia, Austria, Bélgica, Brasil, Chile, Colombia, Egipto, Gran Bretaña, Grecia, Italia, Luxemburgo, México, Nueva Zelanda, Países Bajos, Portugal, Suiza, Turquía |
| Nacua      | Venezuela                                                                                                                                                                                                  |
| Oedemex    | Egipto, Suiza                                                                                                                                                                                              |
| Salurin    | Arabia Saudita, Emiratos Árabes Unidos                                                                                                                                                                     |
| Seguril    | España                                                                                                                                                                                                     |
| Uradex     | Turquía                                                                                                                                                                                                    |
| Uradex     | Turquía                                                                                                                                                                                                    |



## Estabilidad en solución

| PVC | ▲ | 1,2 > 3,2 mg/ml | 22°C |  | 84 |  |  | 1680 |
|-----|---|-----------------|------|--|----|--|--|------|
| PVC | ▲ | 1,2 > 3,2 mg/ml | 22°C |  | 7  |  |  | 1680 |
| PVC | ▲ | 1,2 > 3,2 mg/ml | 6°C  |  | 84 |  |  | 1680 |
| PP  | ▲ | 1,0 > 8,0 mg/ml | 22°C |  | 84 |  |  | 1680 |
| PP  | ▲ | 1,0 > 8,0 mg/ml | 22°C |  | 7  |  |  | 1680 |
| PP  | ▲ | 1,0 > 8,0 mg/ml | 6°C  |  | 84 |  |  | 1680 |
| PP  | ▲ | 5 mg/ml         | 20°C |  | 24 |  |  | 4341 |
| PP  | ▲ | 5 mg/ml         | 4°C  |  | 35 |  |  | 4341 |
| PP  | ◆ | 1 mg/ml         | 25°C |  | 96 |  |  | 3821 |



## Estabilidad en mezcla

|   |   |  |  |   |  |  |   |      |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|------|
|  |  | 0,2 mg/ml                                                                          | 20°C-23°C                                                                          |  | Granisetron hydrochloride : 0,5 mg/ml                                              | 4                                                                                    |  | 57   |
|  |  | 0,5 & 10 mg/ml                                                                     | 20°C-25°C                                                                          |  | Tirofiban : 50 µg/ml                                                               | 4                                                                                    |  | 1603 |
|  |  | 0,5 & 10 mg/ml                                                                     | 20°C-25°C                                                                          |  | Tirofiban : 50 µg/ml                                                               | 4                                                                                    |  | 1603 |
|  |  | 1.07 mg/ml                                                                         | 25°C                                                                               |  | Human albumin : 250 mg/ml                                                          | 48                                                                                   |  | 3490 |
|  |  | 1.07 mg/ml                                                                         | 4°C                                                                                |  | Human albumin : 250 mg/ml                                                          | 14                                                                                   |  | 3490 |
|  |  | 3.33>>10 mg/ml                                                                     | 25°C                                                                               |  | Dexamethasone sodium phosphate : 0.33>>3.33 mg/ml                                  | 3                                                                                    |  | 2205 |
|  |  | 3.33>>10 mg/ml                                                                     | 5°C                                                                                |  | Dexamethasone sodium phosphate : 0.33>>3.33 mg/ml                                  | 3                                                                                    |  | 2205 |
|  |  | 1 mg/ml                                                                            | 25°C                                                                               |  | Chlorothiazide sodium : 10 mg/ml                                                   | 96                                                                                   |  | 3821 |
|  |  | 0,2 mg/ml                                                                          | 25°C                                                                               |  | Cefoperazone sodium : 10 mg/ml                                                     | 2                                                                                    |  | 87   |
|  |  | 0,2 mg/ml                                                                          | 4°C                                                                                |  | Cefoperazone sodium : 10 mg/ml                                                     | 5                                                                                    |  | 87   |



## Factores que influyen sobre la estabilidad

|  |          |   |  |      |
|--|----------|---|--|------|
|  |          | → |  | 796  |
|  | ◆        | → |  | 1855 |
|  | ◆        | → |  | 3639 |
|  | ◆        | → |  | 301  |
|  | pH < 5,5 | → |  | 1289 |



## Compatibilidades

|                                                                                     |                                                                                     |  |    |  |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|                                                                                     |    | Furosemide : 5 mg/ml<br>Alprostadil : 20 µg/ml                                    |    | 4651                                                                                |
|                                                                                     |    | Furosemide : 3 mg/ml<br>Amifostine : 10 mg/ml                                     |    | 3                                                                                   |
|    |    | Furosemide : 0,16 mg/ml<br>Amikacin sulfate : 2 mg/ml                             |    | 367                                                                                 |
|    |    | Furosemide : 0,16 mg/ml<br>Amikacin sulfate : 2 mg/ml                             |    | 367                                                                                 |
|    |    | Furosemide : 10 mg/ml<br>Amiodarone hydrochloride : 15 mg/ml                      |    | 3463                                                                                |
|    |    | Furosemide : 1 mg/ml<br>Amiodarone hydrochloride : 4 mg/ml                        |    | 1232                                                                                |
|                                                                                     |    | Furosemide : 0.2 mg/ml<br>Amiodarone hydrochloride : 1.8 mg/ml                    |    | 242                                                                                 |
|    |    | Furosemide : 10 mg/ml<br>Amiodarone hydrochloride : 6 mg/ml                       |    | 1611                                                                                |
|    |    | Furosemide : 10 mg/ml<br>Amiodarone hydrochloride : 6 mg/ml                       |    | 3210                                                                                |
|                                                                                     |   | Furosemide : 0.2 mg/ml<br>Amiodarone hydrochloride : 1.8 mg/ml                    |   | 242                                                                                 |
|  |  | Furosemide : 5 mg/ml<br>Amiodarone hydrochloride : 18 mg/ml                       |  | 4698                                                                                |
|  |  | Furosemide : 10 mg/ml<br>Amiodarone hydrochloride : 15 mg/ml                      |  | 3823                                                                                |
|  |  | Furosemide : 10 mg/ml<br>Amiodarone hydrochloride : 15 mg/ml                      |  | 3134                                                                                |
|  |  | Furosemide : 10 mg/ml<br>Amiodarone hydrochloride : 15 mg/ml                      |  | 3463                                                                                |
|  |  | Furosemide : 10 mg/ml<br>Amiodarone hydrochloride : 15 mg/ml                      |  | 3823                                                                                |
|                                                                                     |  | Furosemide : 3 mg/ml<br>Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml   |  | 921                                                                                 |
|  |  | Furosemide : 3 mg/ml<br>Amsacrine : 1 mg/ml                                       |  | 253                                                                                 |
|                                                                                     |  | Furosemide : 3 mg/ml<br>Anidulafungin : 0.5 mg/ml                                 |  | 1982                                                                                |
|                                                                                     |  | Furosemide : 10 mg/ml<br>Argatroban : 1 mg/ml                                     |  | 1963                                                                                |
|                                                                                     |  | Furosemide : 3 mg/ml<br>Aztreonam : 40 mg/ml                                      |  | 99                                                                                  |
|                                                                                     |  | Furosemide : 3 mg/ml<br>Bivalirudin : 5 mg/ml                                     |  | 1713                                                                                |
|                                                                                     |  | Furosemide : 10 mg/ml<br>Caffeine : 10 mg/ml                                      |  | 4837                                                                                |
|                                                                                     |  | Furosemide : 10 mg/ml<br>Calcium gluconate : 100 mg/ml                            |  | 3210                                                                                |

|  |  |                                                                      |    |      |
|--|--|----------------------------------------------------------------------|----|------|
|  |  | Furosemide : 3 mg/ml<br>Cefiderocol sulfate tosylate : 20 mg/mL      |    | 4528 |
|  |  | Furosemide : 3 mg/ml<br>Cefiderocol sulfate tosylate : 20 mg/mL      |    | 4528 |
|  |  | Furosemide : 0,2 mg/ml<br>Cefoperazone sodium : 10 mg/ml             |    | 87   |
|  |  | Furosemide : 3 mg/ml<br>Ceftaroline fosamil : 2,22 mg/ml             |    | 3249 |
|  |  | Furosemide : 3 mg/ml<br>Ceftaroline fosamil : 2,22 mg/ml             |    | 3249 |
|  |  | Furosemide : 3 mg/ml<br>Ceftaroline fosamil : 2,22 mg/ml             | RL | 3249 |
|  |  | Furosemide : 3 mg/ml<br>Ceftobiprole medocaril sodium : 2 mg/ml      |    | 2269 |
|  |  | Furosemide : 3 mg/ml<br>Ceftobiprole medocaril sodium : 2 mg/ml      |    | 2269 |
|  |  | Furosemide : 3 mg/ml<br>Ceftobiprole medocaril sodium : 2 mg/ml      | RL | 2269 |
|  |  | Furosemide : 3 mg/ml<br>Ceftolozane / tazobactam : 10/5 mg/ml        |    | 3828 |
|  |  | Furosemide : 3 mg/ml<br>Ceftolozane / tazobactam : 10/5 mg/ml        |    | 3828 |
|  |  | Furosemide : 1 mg/ml<br>Chlorothiazide sodium : 10 mg/ml             |    | 3821 |
|  |  | Furosemide : 5,21 mg/ml<br>Chlorpromazine hydrochloride : 0,26 mg/ml |    | 1289 |
|  |  | Furosemide : 0.4 mg/ml<br>Cimetidine hydrochloride : 3 mg/ml         |    | 1201 |
|  |  | Furosemide : 10 mg/ml<br>Ciprofloxacin lactate : 2 mg/ml             |    | 288  |
|  |  | Furosemide : 10 mg/ml<br>Ciprofloxacin lactate : 2 mg/ml             |    | 288  |
|  |  | Furosemide : 3 mg/ml<br>Cisatracurium besylate : 0.1 mg/ml           |    | 299  |
|  |  | Furosemide : 3 mg/ml<br>Cisatracurium besylate : 2 & 5 mg/ml         |    | 299  |
|  |  | Furosemide : 10 mg/ml<br>Cisatracurium besylate : 5 mg/ml            | Ø  | 3134 |
|  |  | Furosemide : 3 mg/ml<br>Cladribine : 0.5 mg/ml                       |    | 1496 |
|  |  | Furosemide<br>Conivaptan                                             | RL | 3718 |
|  |  | Furosemide : 1 mg/ml<br>Diazepam : 1 mg/ml                           |    | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Diltiazem hydrochloride : 5 mg/ml           | Ø  | 3210 |
|  |  | Furosemide : 10 mg/ml<br>Dobutamine hydrochloride : 5 mg/ml          | Ø  | 3210 |
|  |  | Furosemide : 1 mg/ml<br>Dobutamine hydrochloride : 1 mg/ml           |    | 1058 |
|  |  | Furosemide : 10 mg/ml<br>Dobutamine hydrochloride : 2 mg/ml          |    | 1041 |

|  |  |                                                                            |  |      |
|--|--|----------------------------------------------------------------------------|--|------|
|  |  | Furosemide : 1 mg/ml<br>Dobutamine hydrochloride : 1 mg/ml                 |  | 1058 |
|  |  | Furosemide : 2 mg/ml<br>Dobutamine hydrochloride : 8 mg/ml                 |  | 1506 |
|  |  | Furosemide : 3 mg/ml<br>Docetaxel : 0.9 mg/ml                              |  | 1754 |
|  |  | Furosemide : 2 mg/ml<br>Dopamine hydrochloride : 8 mg/ml                   |  | 1506 |
|  |  | Furosemide : 10 mg/ml<br>Dopamine hydrochloride : 3,2 mg/ml                |  | 3210 |
|  |  | Furosemide : 2 mg/ml<br>Dopamine hydrochloride : 8 mg/ml                   |  | 1506 |
|  |  | Furosemide : 3 mg/ml<br>Doripenem : 5 mg/ml                                |  | 2262 |
|  |  | Furosemide : 3 mg/ml<br>Doripenem : 5 mg/ml                                |  | 2262 |
|  |  | Furosemide : 3 mg/ml<br>Doxorubicin hydrochloride liposome peg : 0.4 mg/ml |  | 251  |
|  |  | Furosemide : 10 mg/ml<br>Droperidol : 2.5 mg/ml                            |  | 1088 |
|  |  | Furosemide : 10 mg/ml<br>Epinephrine hydrochloride : 200 µg/ml             |  | 3210 |
|  |  | Furosemide : 10 mg/ml<br>Esmolol hydrochloride : 10 mg/ml                  |  | 3210 |
|  |  | Furosemide : 10 mg/ml<br>Esmolol hydrochloride : 10 mg/ml                  |  | 523  |
|  |  | Furosemide : 10 mg/ml<br>Esmolol hydrochloride : 10 mg/ml                  |  | 523  |
|  |  | Furosemide : 3 mg/ml<br>Etoposide phosphate : 5 mg/ml                      |  | 1410 |
|  |  | Furosemide : 0.8 mg/ml<br>Famotidine : 0.2 mg/ml                           |  | 398  |
|  |  | Furosemide : 10 mg/ml<br>Famotidine                                        |  | 397  |
|  |  | Furosemide : 10 mg/ml<br>Fentanyl citrate : 50 µg/ml                       |  | 63   |
|  |  | Furosemide : 3 mg/ml<br>Filgrastim : 30 µg/ml                              |  | 244  |
|  |  | Furosemide : 3 mg/ml<br>Fludarabine phosphate : 1 mg/ml                    |  | 492  |
|  |  | Furosemide : 10 mg/ml<br>Foscarnet sodium : 24 mg/ml                       |  | 73   |
|  |  | Furosemide : 3 mg/ml<br>Fosfomycin : 30 mg/ml                              |  | 4055 |
|  |  | Furosemide : 3 mg/ml<br>Fosfomycin : 30 mg/ml                              |  | 4055 |
|  |  | Furosemide : 0,8 mg/ml<br>Gentamicin sulfate : 1,6 mg/ml                   |  | 367  |
|  |  | Furosemide : 0,8 mg/ml<br>Gentamicin sulfate : 1,6 mg/ml                   |  | 367  |
|  |  | Furosemide : 3 mg/ml<br>Granisetron hydrochloride : 0,05 mg/ml             |  | 49   |

|  |  |                                                                     |    |      |
|--|--|---------------------------------------------------------------------|----|------|
|  |  | Furosemide : 10 mg/ml<br>Haloperidol lactate : 0,5 mg/ml            | Ø  | 3134 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 1 UI/ml                   | ▲  | 1228 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 10 UI/ml                  | Ø  | 3210 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 1 UI/ml                   | ◆  | 1228 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 100 UI/ml                 | ◆  | 4724 |
|  |  | Furosemide : 5,21 mg/ml<br>Heparin sodium : 58,34 UI/ml             | ◆  | 1289 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 500 UI/ml                 | Ø  | 3134 |
|  |  | Furosemide : 10 mg/ml<br>Hydrocortisone sodium succinate : 1 mg/ml  | RL | 1228 |
|  |  | Furosemide                                                          | ◆  | 3639 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 1 UI/ml                   | RL | 1228 |
|  |  | Furosemide : 10 mg/ml<br>Hydrocortisone sodium succinate : 1 mg/ml  | ◆  | 1228 |
|  |  | Furosemide : 10 mg/ml<br>Hydrocortisone sodium succinate : 1 mg/ml  | ▲  | 1228 |
|  |  | Furosemide : 10 mg/ml<br>Imipenem-Cilastatin / Relebactam : 5 mg/ml | ▲  | 4433 |
|  |  | Furosemide : 10 mg/ml<br>Imipenem-Cilastatin / Relebactam : 5 mg/ml | ◆  | 4433 |
|  |  | Furosemide : 10 mg/ml<br>Insulin : 2 UI/ml                          | Ø  | 3134 |
|  |  | Furosemide : 10 mg/ml<br>Insulin : 1 UI/ml                          | Ø  | 3210 |
|  |  | Furosemide : 1 & 5 mg/ml<br>Insulin aspart : 1 UI/ml                | ▲  | 1508 |
|  |  | Furosemide : 1 & 5 mg/ml<br>Insulin aspart : 1 UI/ml                | ◆  | 1508 |
|  |  | Furosemide : 3 mg/ml<br>Isavuconazonium sulfate : 1.5 mg/ml         | ▲  | 3829 |
|  |  | Furosemide : 3 mg/ml<br>Isavuconazonium sulfate : 1.5 mg/ml         | ◆  | 3829 |
|  |  | Furosemide : 1 mg/ml<br>Isoprenaline hydrochloride : 0,004 mg/ml    | ◆  | 1232 |
|  |  | Furosemide : 0,16 mg/ml<br>Kanamycin sulfate : 2 mg/ml              | ▲  | 367  |
|  |  | Furosemide : 0,16 mg/ml<br>Kanamycin sulfate : 2 mg/ml              | ◆  | 367  |
|  |  | Furosemide : 10 mg/ml<br>Labetalol hydrochloride : 5 mg/ml          | Ø  | 3210 |
|  |  | Furosemide : 10 mg/ml<br>Labetalol hydrochloride : 1.6 mg/ml        | ◆  | 89   |
|  |  | Furosemide : 10 mg/ml<br>Levofloxacin : 5 mg/ml                     | ◆  | 1072 |



|  |  |                                                                       |   |      |
|--|--|-----------------------------------------------------------------------|---|------|
|  |  | Furosemide : 3 mg/ml<br>Linezolid : 2 mg/ml                           | Ø | 1925 |
|  |  | Furosemide : 10 mg/ml<br>Magnesium sulfate : 200 mg/ml                | Ø | 3210 |
|  |  | Furosemide : 2 mg/ml<br>Methadone hydrochloride : 0.2 mg/ml           | ♦ | 1506 |
|  |  | Furosemide : 2 mg/ml<br>Methadone hydrochloride : 0.2 mg/ml           | ▲ | 1506 |
|  |  | Furosemide : 10 mg/ml<br>Metoprolol tartrate : 1 mg/ml                | Ø | 2346 |
|  |  | Furosemide : 10 mg/ml<br>Midazolam hydrochloride : 5 mg/ml            | Ø | 186  |
|  |  | Furosemide : 10 mg/ml<br>Midazolam hydrochloride : 2,1 mg/ml          | Ø | 3134 |
|  |  | Furosemide : 10 mg/ml<br>Midazolam hydrochloride : 1 mg/ml            | ♦ | 176  |
|  |  | Furosemide : 4 & 5 mg/ml<br>Milrinone lactate : 0.100 & 0.350 mg/ml   | ♦ | 191  |
|  |  | Furosemide : 0.8 >> 10 mg/ml<br>Morphine sulfate : 1 mg/ml            | ♦ | 62   |
|  |  | Furosemide : 10 mg/ml<br>N-acetylcysteine : 200 mg/ml                 | Ø | 3766 |
|  |  | Furosemide : 1 mg/ml<br>Nalbuphine hydrochloride : 0,05 >> 0,33 mg/ml | ▲ | 4867 |
|  |  | Furosemide : 1 mg/ml<br>Nalbuphine hydrochloride : 0,05 >> 0,33 mg/ml | ♦ | 4867 |
|  |  | Furosemide : 10 mg/ml<br>Naloxone hydrochloride : 0.4 mg/ml           | Ø | 3408 |
|  |  | Furosemide : 0,4 mg/ml<br>Netilmicin sulfate : 1,5 mg/ml              | ▲ | 367  |
|  |  | Furosemide : 0,4 mg/ml<br>Netilmicin sulfate : 1,5 mg/ml              | ♦ | 367  |
|  |  | Furosemide : 10 mg/ml<br>Nimodipine : 0.2 mg/ml                       | Ø | 3134 |
|  |  | Furosemide : 10 mg/ml<br>Nitroglycerin : 0.2 mg/ml                    | Ø | 3134 |
|  |  | Furosemide : 0.67 mg/ml<br>Nitroglycerin : 0.4 mg/ml                  | ▲ | 1049 |
|  |  | Furosemide : 10 mg/ml<br>Nitroglycerin : 1 mg/ml                      | Ø | 3210 |
|  |  | Furosemide : 10 mg/ml<br>Nitroglycerin : 0.2 mg/ml                    | ▲ | 3823 |
|  |  | Furosemide : 10 mg/ml<br>Norepinephrine bitartrate : 0.1 mg/ml        | Ø | 3210 |
|  |  | Furosemide : 2.4 mg/ml<br>Pethidine hydrochloride : 10 mg/ml          | ♦ | 62   |
|  |  | Furosemide : 10 mg/ml<br>Phenylephrine hydrochloride : 1 mg/ml        | Ø | 3210 |
|  |  | Furosemide : 4 mg/ml<br>Phenylephrine hydrochloride : 0.64 mg/ml      | ▲ | 2116 |
|  |  | Furosemide : 10 mg/ml<br>Potassium chloride : 40 mEq/l                | ▲ | 1228 |

|  |                                                               |   |      |
|--|---------------------------------------------------------------|---|------|
|  | Furosemide : 10 mg/ml<br>Procainamide hydrochloride : 8 mg/ml | Ø | 3210 |
|  | Furosemide : 10 mg/ml<br>Salbutamol sulfate : 1 mg/ml         | Ø | 3216 |
|  | Furosemide : 10 mg/ml<br>Sodium bicarbonate : 84 mg/ml        | Ø | 3212 |
|  | Furosemide : 10 mg/ml                                         |   | 4507 |
|  | Furosemide : 3 mg/ml                                          |   | 1415 |
|  | Furosemide : 10 mg/ml                                         |   | 3948 |
|  | Furosemide : 3 mg/ml<br>Propofol : 10 mg/ml                   | Ø | 300  |
|  | Furosemide : 10 mg/ml<br>Sodium bicarbonate : 84 mg/ml        | Ø | 3210 |
|  | Furosemide : 10 mg/ml<br>Sodium bicarbonate : 84 mg/ml        | Ø | 3134 |
|  | Furosemide : 10 mg/ml<br>Sugammadex : 100 mg/ml               | Ø | 3372 |
|  | Furosemide : 0,5 & 10 mg/ml<br>Tirofiban : 50 µg/ml           |   | 1603 |
|  | Furosemide : 10 mg/ml<br>Urapidil : 5 mg/ml                   | Ø | 3134 |
|  | Furosemide : 0.11 mg/ml                                       |   | 1338 |
|  | Furosemide : 10 mg/ml<br>Thiopental sodium : 60 mg/ml         | Ø | 3134 |
|  | Furosemide : 0,8 mg/ml<br>Tobramycin sulfate : 1,6 mg/ml      |   | 367  |
|  | Furosemide : 10 mg/ml<br>Vasopressin : 1 UI/ml                | Ø | 3210 |
|  | Furosemide : 3 mg/ml                                          |   | 301  |
|  | Furosemide                                                    |   | 3985 |
|  | Furosemide : 3 mg/ml<br>Telavancin hydrochloride : 7,5 mg/ml  |   | 3254 |
|  | Furosemide : 4 mg/ml<br>Vasopressin : 0.4 UI/ml               |   | 2116 |
|  | Furosemide : 10 mg/ml                                         |   | 316  |
|  | Furosemide : 10 mg/ml                                         |   | 3948 |
|  | Furosemide : 10 mg/ml                                         |   | 939  |
|  | Furosemide : 10 mg/ml                                         |   | 3134 |
|  | Furosemide : 1 mg/ml<br>Sufentanil citrate : 0.005 mg/ml      |   | 3294 |
|  | Furosemide : 0,2 >>0,9 mg/ml                                  |   | 4426 |
|  | Furosemide : 0.67 mg/ml<br>Nitroglycerin : 0.4 mg/ml          |   | 1049 |
|  | Furosemide : 10 mg/ml<br>Nitroglycerin : 0.2 mg/ml            |   | 3823 |



|  |  |                                                                       |    |      |
|--|--|-----------------------------------------------------------------------|----|------|
|  |  | Furosemide : 10 mg/ml<br>Norepinephrine bitartrate : 0,1 mg/ml        |    | 4570 |
|  |  | Furosemide : 1 mg/ml<br>Norepinephrine bitartrate : 0,1 mg/ml         |    | 4570 |
|  |  | Furosemide : 5 mg/ml<br>Oritavancin : 0.8 >>2 mg/ml                   |    | 3152 |
|  |  | Furosemide : 3 mg/ml<br>Oxaliplatin : 0,5 mg/ml                       |    | 1662 |
|  |  | Furosemide : 3 mg/ml<br>Paclitaxel : 1.2 mg/ml                        |    | 248  |
|  |  | Furosemide : 0.8 mg/ml<br>Pethidine hydrochloride : 10 mg/ml          |    | 62   |
|  |  | Furosemide : 10 mg/ml<br>Pethidine hydrochloride : 10 mg/ml           |    | 62   |
|  |  | Furosemide : 4 mg/ml<br>Phenylephrine hydrochloride : 0.64 mg/ml      |    | 2116 |
|  |  | Furosemide : 3 mg/ml<br>Piperacillin sodium / tazobactam : 40/5 mg/ml |    | 81   |
|  |  | Furosemide : 10 mg/ml<br>Potassium chloride : 40 mEq/l                |    | 1228 |
|  |  | Furosemide : 5,21 mg/ml<br>Potassium chloride : 1250 mEq/l            |    | 1289 |
|  |  | Furosemide : 10 mg/ml<br>Potassium chloride : 40 mEq/l                | RL | 1228 |
|  |  | Furosemide : 1 mg/ml<br>Remifentanyl hydrochloride : 120 µg/ml        |    | 3294 |
|  |  | Furosemide : 1 mg/ml<br>Remifentanyl hydrochloride : 120 µg/ml        |    | 3176 |
|  |  | Furosemide : 1 mg/ml<br>Sildenafil citrate : 0.06 mg/ml               |    | 4845 |
|  |  | Furosemide : 0,2 mg/ml<br>Sildenafil citrate : 0,6 mg/ml              |    | 4845 |
|  |  | Furosemide : 1 mg/ml<br>Sildenafil citrate : 0,6 mg/ml                |    | 4845 |
|  |  | Furosemide : 0.2 mg/ml<br>Sildenafil citrate : 0.06 mg/ml             |    | 4845 |
|  |  | Furosemide : 3 mg/ml<br>Telavancin hydrochloride : 7.5 mg/ml          | RL | 3254 |
|  |  | Furosemide : 3 mg/ml<br>Telavancin hydrochloride : 7,5 mg/ml          |    | 3254 |
|  |  | Furosemide : 3 mg/ml<br>Teniposide : 0.1 mg/ml                        |    | 905  |
|  |  | Furosemide : 3 mg/ml<br>Thiotepa : 1 mg/ml                            |    | 249  |
|  |  | Furosemide : 0,5 & 10 mg/ml<br>Tirofiban : 50 µg/ml                   |    | 1603 |
|  |  | Furosemide : 0,8 mg/ml<br>Tobramycin sulfate : 1,6 mg/ml              |    | 367  |
|  |  | Furosemide : 10 mg/ml<br>Vancomycin hydrochloride : 10 mg/ml          |    | 3385 |
|  |  | Furosemide : 4 mg/ml<br>Vasopressin : 0.4 UI/ml                       |    | 2116 |

|  |  |                                                                              |    |      |
|--|--|------------------------------------------------------------------------------|----|------|
|  |  | Furosemide : 0.2 mg/ml<br>Verapamil hydrochloride : 0.08 mg/ml               |    | 1057 |
|  |  | Furosemide : 10 mg/ml                                                        |    | 4515 |
|  |  | Furosemide : 10 mg/ml                                                        | RL | 4603 |
|  |  | Furosemide                                                                   | RL | 5093 |
|  |  | Furosemide : 2 mg/ml                                                         |    | 3967 |
|  |  | Furosemide : 2 mg/ml                                                         |    | 4370 |
|  |  | Furosemide : 0.2 mg/ml<br>Verapamil hydrochloride : 0.08 mg/ml               |    | 1057 |
|  |  | Furosemide                                                                   |    | 5093 |
|  |  | Furosemide : 3 mg/ml<br>Allopurinol sodium : 3 mg/ml                         |    | 307  |
|  |  | Furosemide : 5 mg/ml<br>Alprostadil : 15 µg/ml                               |    | 3201 |
|  |  | Furosemide : 10 mg/ml<br>Alprostadil : 1 µg/ml                               |    | 4570 |
|  |  | Furosemide : 5 mg/ml<br>Alprostadil : 20 µg/ml                               |    | 4491 |
|  |  | Furosemide : 1 mg/ml<br>Aminophylline : 1 mg/ml                              |    | 1232 |
|  |  | Furosemide<br>Amiodarone hydrochloride                                       |    | 3465 |
|  |  | Furosemide<br>Amiodarone hydrochloride                                       |    | 3464 |
|  |  | Furosemide : 10 mg/ml<br>Amoxicillin sodium / clavulanic acid : 100/10 mg/ml |    | 3824 |
|  |  | Furosemide : 1 mg/ml<br>Ampicillin sodium : 20 mg/ml                         |    | 1232 |
|  |  | Furosemide : 1 mg/ml<br>Atropine sulfate : 0,06 mg/ml                        |    | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Azithromycine : 2 mg/ml                             |    | 1800 |
|  |  | Furosemide<br>Bleomycin sulfate                                              |    | 4154 |
|  |  | Furosemide<br>Bleomycin sulfate                                              |    | 3646 |
|  |  | Furosemide : 2.9 mg/ml<br>Blinatumomab : 0.125 & 0.375 µg/ml                 |    | 3976 |
|  |  | Furosemide : 1 mg/ml<br>Bumetanide : 0,006 mg/ml                             |    | 1232 |
|  |  | Furosemide : 1 mg/ml<br>Buprenorphine hydrochloride : 0,075 mg/ml            |    | 1232 |
|  |  | Furosemide : 1 mg/ml<br>Calcium gluconate : 2 mg/ml                          |    | 1232 |
|  |  | Furosemide : 3 mg/ml<br>Caspofungin acetate : 0,7 mg/ml                      |    | 2247 |
|  |  | Furosemide : 10 mg/ml<br>Caspofungin acetate : 0.5 mg/ml                     |    | 2233 |

|  |                                                                                  |  |      |
|--|----------------------------------------------------------------------------------|--|------|
|  | Furosemide : 1 mg/ml<br>Cefamandole nafate : 20 mg/ml                            |  | 1232 |
|  | Furosemide : 10 mg/ml<br>Cefepime dihydrochloride : 125 mg/ml                    |  | 2141 |
|  | Furosemide : 10 mg/ml<br>Cefmetazole sodium : 100 mg/ml                          |  | 93   |
|  | Furosemide : 10 mg/ml<br>Ceftazidime : 83.3 mg/ml                                |  | 1759 |
|  | Furosemide : 10 mg/ml<br>Ceftazidime : 125 mg/ml                                 |  | 2141 |
|  | Furosemide : 1 mg/ml<br>Cefuroxime sodium : 37,5 mg/ml                           |  | 1232 |
|  | Furosemide : 1 mg/ml<br>Chlorpromazine hydrochloride : 5 mg/ml                   |  | 1232 |
|  | Furosemide : 1 mg/ml<br>Cimetidine hydrochloride : 4 mg/ml                       |  | 1232 |
|  | Furosemide : 5 mg/ml<br>Ciprofloxacin lactate : 2 mg/ml                          |  | 289  |
|  | Furosemide : 10 mg/ml<br>Cisatracurium besylate : 5 mg/ml                        |  | 3823 |
|  | Furosemide : 10 mg/ml<br>Cisatracurium besylate : 5 mg/ml                        |  | 3463 |
|  | Furosemide<br>Cisatracurium besylate                                             |  | 3465 |
|  | Furosemide : 3 mg/ml<br>Cladribine : 0.015 mg/ml                                 |  | 1496 |
|  | Furosemide : 1.2 & 10 mg/ml<br>Clonidine hydrochloride : 0.009 & 0.03 mg/ml      |  | 4130 |
|  | Furosemide : 2 mg/ml<br>Clonidine hydrochloride : 0.0075 mg/ml                   |  | 1506 |
|  | Furosemide : 1 mg/ml<br>Cloxacillin sodium : 20 mg/ml                            |  | 1232 |
|  | Furosemide : 10 mg/ml<br>Cloxacillin sodium : 100 mg/ml                          |  | 3012 |
|  | Furosemide<br>Daunorubicin/cytarabine liposomale : 0,4 mg/mL                     |  | 4654 |
|  | Furosemide : 10 mg/ml<br>Defibrotide : 8 mg/ml                                   |  | 3728 |
|  | Furosemide : 3.33>>10 mg/ml<br>Dexamethasone sodium phosphate : 0.33>>3.33 mg/ml |  | 2205 |
|  | Furosemide : 1 mg/ml<br>Dexamethasone sodium phosphate : 4 mg/ml                 |  | 1232 |
|  | Furosemide : 10 mg/ml<br>Dexmedetomidine : 4 µg/ml                               |  | 4570 |
|  | Furosemide : 3 mg/ml<br>Dexmedetomidine : 4 µg/ml                                |  | 1712 |
|  | Furosemide : 1 mg/ml<br>Diamorphine hydrochloride : 0,5 mg/ml                    |  | 1232 |
|  | Furosemide : 10 mg/ml<br>Diclofenac : 3 mg/ml                                    |  | 3823 |
|  | Furosemide : 1 mg/ml<br>Digoxin : 25 µg/ml                                       |  | 1232 |

|  |  |                                                                     |  |      |
|--|--|---------------------------------------------------------------------|--|------|
|  |  | Furosemide : 10 mg/ml<br>Diltiazem hydrochloride : 1 & 5 mg/ml      |  | 198  |
|  |  | Furosemide : 10 mg/ml<br>Diltiazem hydrochloride : 1 mg/ml          |  | 314  |
|  |  | Furosemide<br>Dimenhydrinate                                        |  | 2087 |
|  |  | Furosemide : 2 mg/ml<br>Dobutamine hydrochloride : 8 mg/ml          |  | 1506 |
|  |  | Furosemide : 10 mg/ml<br>Dobutamine hydrochloride : 4 mg/ml         |  | 314  |
|  |  | Furosemide : 1 mg/ml<br>Dobutamine hydrochloride : 0.5 mg/ml        |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Dopamine hydrochloride : 3,2 mg/ml         |  | 4389 |
|  |  | Furosemide : 10 mg/ml<br>Dopamine hydrochloride : 3.2 mg/ml         |  | 314  |
|  |  | Furosemide<br>Doxapram hydrochloride                                |  | 3612 |
|  |  | Furosemide : 10 mg/ml<br>Doxorubicin hydrochloride : 2 mg/ml        |  | 763  |
|  |  | Furosemide : 10 mg/ml<br>Droperidol : 2,5 mg/ml                     |  | 763  |
|  |  | Furosemide : 2.5 mg/ml<br>Enalaprilate : 0.0125 mg/ml               |  | 1703 |
|  |  | Furosemide : 1 mg/ml<br>Epinephrine hydrochloride : 16 & 100 µg/ml  |  | 4570 |
|  |  | Furosemide : 10 mg/ml<br>Epinephrine hydrochloride : 20 µg/ml       |  | 314  |
|  |  | Furosemide : 1 mg/ml<br>Epinephrine hydrochloride : 8 µg/ml         |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Epinephrine hydrochloride : 16 & 100 µg/ml |  | 4570 |
|  |  | Furosemide<br>Eptifibatide                                          |  | 3934 |
|  |  | Furosemide : 3 mg/ml<br>Eravacycline : 0,6 mg/ml                    |  | 4434 |
|  |  | Furosemide : 1 mg/ml<br>Erythromycin lactobionate : 5 mg/ml         |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Esmolol hydrochloride : 10 mg/ml           |  | 3823 |
|  |  | Furosemide : 10 mg/ml<br>Esmolol hydrochloride : 10 mg/ml           |  | 3664 |
|  |  | Furosemide<br>Esmolol hydrochloride                                 |  | 3607 |
|  |  | Furosemide : 1 mg/ml<br>Esmolol hydrochloride : 20 mg/ml            |  | 4570 |
|  |  | Furosemide : 2 mg/ml<br>Esomeprazole sodium : 0.32 mg/ml            |  | 1506 |
|  |  | Furosemide : 3 mg/ml<br>Famotidine : 2 mg/ml                        |  | 215  |
|  |  | Furosemide : 3 mg/ml<br>Fenoldopam mesylate : 80 µg/ml              |  | 1803 |

|  |  |                                                                    |  |      |
|--|--|--------------------------------------------------------------------|--|------|
|  |  | Furosemide : 10 mg/ml<br>Fentanyl citrate : 50 µg/ml               |  | 314  |
|  |  | Furosemide : 1 mg/ml<br>Flucloxacillin sodium : 20 mg/ml           |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Fluconazole : 2 mg/ml                     |  | 496  |
|  |  | Furosemide : 10 mg/ml<br>Fluorouracil : 50 mg/ml                   |  | 763  |
|  |  | Furosemide : 10 mg/ml<br>Folate calcium : 10 mg/ml                 |  | 763  |
|  |  | Furosemide : 10 mg/ml<br>Gallium nitrate : 1 mg/ml                 |  | 91   |
|  |  | Furosemide : 3 mg/ml<br>Gemcitabine hydrochloride : 10 mg/ml       |  | 1423 |
|  |  | Furosemide : 10 mg/ml<br>Gentamicin sulfate : 10 mg/ml             |  | 789  |
|  |  | Furosemide : 5 mg/ml<br>Gentamicin sulfate : 6.4 mg/ml             |  | 805  |
|  |  | Furosemide : 1 mg/ml<br>Gentamicin sulfate : 8 mg/ml               |  | 1232 |
|  |  | Furosemide : 5 mg/ml<br>Glycerophosphate disodium                  |  | 4332 |
|  |  | Furosemide : 0.4 mg/ml<br>Granisetron hydrochloride : 1 mg/ml      |  | 57   |
|  |  | Furosemide : 10 mg/ml<br>Haloperidol lactate : 0,5 mg/ml           |  | 3463 |
|  |  | Furosemide : 10 mg/ml<br>Haloperidol lactate : 0,5 mg/ml           |  | 3823 |
|  |  | Furosemide<br>Haloperidol lactate                                  |  | 3465 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 500 UI/ml                |  | 3823 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 1000 UI/ml               |  | 763  |
|  |  | Furosemide : 1 mg/ml<br>Heparin sodium : 20 UI/ml                  |  | 1232 |
|  |  | Furosemide<br>Heparin sodium                                       |  | 3465 |
|  |  | Furosemide : 10 mg/ml<br>Heparin sodium : 100 UI/ml                |  | 314  |
|  |  | Furosemide : 3 mg/ml<br>Hetastarch : 60 mg/ml                      |  | 1721 |
|  |  | Furosemide<br>Hyaluronidase                                        |  | 3617 |
|  |  | Furosemide<br>Hyaluronidase                                        |  | 3184 |
|  |  | Furosemide : 1 mg/ml<br>Hydrocortisone sodium succinate : 50 mg/ml |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Hydromorphone hydrochloride : 1 mg/ml     |  | 314  |
|  |  | Furosemide : 10 mg/ml<br>Ibuprofen lysinate : 10 mg/ml             |  | 4419 |

|                                                                                     |                                                                                     |                                                                   |                                                                                      |      |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------|------|
|     |     | Furosemide : 0,8 & 10 mg/ml<br>Idarubicin hydrochloride : 1 mg/ml |     | 491  |
|                                                                                     |    | Furosemide : 10 mg/ml<br>Indomethacin sodium trihydrate : 1 mg/ml |    | 467  |
|                                                                                     |    | Furosemide : 10 mg/ml<br>Insulin : 2 UI/ml                        |    | 3823 |
|                                                                                     |    | Furosemide<br>Insulin                                             |                                                                                      | 3465 |
|                                                                                     |    | Furosemide : 1 mg/ml<br>Isosorbide dinitrate : 1 mg/ml            |                                                                                      | 1232 |
|    |    | Furosemide : 10 mg/ml<br>Ketamine hydrochloride : 50 mg/ml        |                                                                                      | 2109 |
|    |    | Furosemide : 10 mg/ml<br>Labetalol hydrochloride : 2 mg/ml        |                                                                                      | 314  |
|    |    | Furosemide : 3 mg/ml<br>Lansoprazole : 0.55 mg/ml                 |    | 1625 |
|                                                                                     |    | Furosemide : 10 mg/ml<br>Levosimendan : 0,025 & 0,05 mg/ml        |                                                                                      | 4571 |
|                                                                                     |    | Furosemide : 1 mg/ml<br>Lidocaine hydrochloride : 2 mg/ml         |    | 1232 |
|                                                                                     |    | Furosemide : 10 mg/ml<br>Lorazepam : 0.5 mg/ml                    |                                                                                      | 314  |
|                                                                                     |    | Furosemide : 10 mg/ml<br>Lorazepam : 0.33 mg/ml                   |    | 186  |
|   |   | Furosemide : 10 mg/ml<br>Magnesium sulfate : 6 mg/ml              |                                                                                      | 4698 |
|                                                                                     |  | Furosemide : 10 mg/ml<br>Mannitol : 200 mg/ml                     |  | 3823 |
|                                                                                     |  | Furosemide : 3 mg/ml<br>Melphalan : 0.1 mg/ml                     |  | 169  |
|                                                                                     |  | Furosemide : 10 mg/ml<br>Meropenem : 1 & 50 mg/ml                 |  | 266  |
|                                                                                     |  | Furosemide : 1 mg/ml<br>Meropenem : 1 & 20 mg/ml                  |  | 266  |
|                                                                                     |  | Furosemide : 10 mg/ml<br>Meropenem : 50 mg/ml                     |  | 4319 |
|                                                                                     |  | Furosemide : 10 mg/ml<br>Methotrexate sodium : 25 mg/ml           |                                                                                      | 1088 |
|                                                                                     |  | Furosemide : 10 mg/ml<br>Methotrexate sodium : 25 mg/ml           |                                                                                      | 763  |
|  |  | Furosemide : 1 mg/ml<br>Metoclopramide hydrochloride : 1 mg/ml    |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Metoclopramide hydrochloride : 5 mg/ml   |                                                                                      | 763  |
|                                                                                     |  | Furosemide : 3 mg/ml<br>Micafungin : 1.5 mg/ml                    |  | 2108 |
|  |  | Furosemide : 10 mg/ml<br>Midazolam hydrochloride : 2 mg/ml        |                                                                                      | 314  |
|  |  | Furosemide : 10 mg/ml<br>Midazolam hydrochloride : 1 mg/ml        |  | 4605 |
|  |  | Furosemide<br>Midazolam hydrochloride                             |                                                                                      | 3465 |



|  |                                                                        |  |      |
|--|------------------------------------------------------------------------|--|------|
|  | Furosemide : 0.08 mg/ml<br>Midazolam hydrochloride : 0.05 & 0.25 mg/ml |  | 1888 |
|  | Furosemide<br>Midazolam hydrochloride                                  |  | 3781 |
|  | Furosemide : 2,5 mg/ml<br>Midazolam hydrochloride : 1 mg/ml            |  | 4605 |
|  | Furosemide : 10 mg/ml<br>Midazolam hydrochloride : 2,1 mg/ml           |  | 3463 |
|  | Furosemide : 10 mg/ml<br>Midazolam hydrochloride : 2,1 mg/ml           |  | 3823 |
|  | Furosemide<br>Milrinone lactate                                        |  | 4987 |
|  | Furosemide : 10 mg/ml<br>Milrinone lactate : 1 mg/ml                   |  | 4506 |
|  | Furosemide : 10 mg/ml<br>Milrinone lactate : 0.2 mg/ml                 |  | 314  |
|  | Furosemide<br>Morphine sulfate                                         |  | 3531 |
|  | Furosemide : 10 mg/ml<br>Morphine sulfate : 2 mg/ml                    |  | 314  |
|  | Furosemide : 1 mg/ml<br>Morphine sulfate : 1 mg/ml                     |  | 1232 |
|  | Furosemide : 10 mg/ml<br>Nefopam : 1,7 mg/ml                           |  | 4698 |
|  | Furosemide : 10 mg/ml<br>Nicardipine hydrochloride : 1 mg/ml           |  | 314  |
|  | Furosemide<br>Nicardipine hydrochloride                                |  | 3941 |
|  | Furosemide<br>Nicardipine hydrochloride                                |  | 3614 |
|  | Furosemide : 10 mg/ml<br>Nimodipine : 0.2 mg/ml                        |  | 3823 |
|  | Furosemide : 10 mg/ml<br>Nitroglycerin : 0.4 mg/ml                     |  | 314  |
|  | Furosemide<br>Nitroglycerin                                            |  | 3465 |
|  | Furosemide : 1 mg/ml<br>Norepinephrine bitartrate : 0,016 mg/ml        |  | 4570 |
|  | Furosemide : 10 mg/ml<br>Norepinephrine bitartrate : 0,016 mg/ml       |  | 4570 |
|  | Furosemide : 10 mg/ml<br>Norepinephrine bitartrate : 0.128 mg/ml       |  | 314  |
|  | Furosemide : 10 mg/ml<br>Omeprazole sodium : 1.6 mg/ml                 |  | 3823 |
|  | Furosemide : 3 mg/ml<br>Ondansetron hydrochloride : 1 mg/ml            |  | 334  |
|  | Furosemide<br>Pantoprazole sodium                                      |  | 2090 |
|  | Furosemide : 1 >> 2 mg/ml<br>Pantoprazole sodium : 0.16 >> 0.8 mg/ml   |  | 1902 |
|  | Furosemide : 10 mg/ml<br>Paracetamol : 10 mg/ml                        |  | 4698 |

|  |  |                                                                     |  |      |
|--|--|---------------------------------------------------------------------|--|------|
|  |  | Furosemide : 10 mg/ml<br>Paracetamol : 10 mg/ml                     |  | 4742 |
|  |  | Furosemide : 1 mg/ml<br>Pethidine hydrochloride : 5 mg/ml           |  | 1232 |
|  |  | Furosemide : 3 mg/ml<br>Plazomicin sulfate : 24 mg/ml               |  | 4145 |
|  |  | Furosemide : 0,8 mg/ml<br>Posaconazole : 1,2 mg/ml                  |  | 4521 |
|  |  | Furosemide : 1 mg/ml<br>Potassium chloride : 40 mEq/l               |  | 1232 |
|  |  | Furosemide : 1 & 10 mg/ml<br>Potassium phosphate                    |  | 3781 |
|  |  | Furosemide : 1 mg/ml<br>Prochlorperazine edisylate : 1.25 mg/ml     |  | 1232 |
|  |  | Furosemide : 1 mg/ml<br>Promethazine hydrochloride : 5 mg/ml        |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Propofol                                   |  | 4524 |
|  |  | Furosemide : 10 mg/ml<br>Ranitidine hydrochloride : 1 mg/ml         |  | 314  |
|  |  | Furosemide : 1 mg/ml<br>Ranitidine hydrochloride : 0,5 mg/ml        |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Remdesivir : 1 mg/ml                       |  | 4768 |
|  |  | Furosemide : 3 mg/ml<br>Remifentanyl hydrochloride : 25 & 250 µg/ml |  | 59   |
|  |  | Furosemide<br>Rocuronium bromide                                    |  | 3564 |
|  |  | Furosemide : 3 mg/ml<br>Sargramostim : 10 µg/ml                     |  | 335  |
|  |  | Furosemide : 1 mg/ml<br>Scopolamine N-butyl bromide                 |  | 1232 |
|  |  | Furosemide : 1 mg/ml<br>Sodium bicarbonate : 84 mg/ml               |  | 1232 |
|  |  | Furosemide<br>Sodium bicarbonate                                    |  | 3466 |
|  |  | Furosemide<br>Sodium bicarbonate                                    |  | 3465 |
|  |  | Furosemide : 10 mg/ml<br>Sodium bicarbonate : 84 mg/ml              |  | 3823 |
|  |  | Furosemide : 10 mg/ml<br>Spiramycine adipate : 60 MUI/ml            |  | 4698 |
|  |  | Furosemide : 3 mg/ml<br>Sulbactam/durlobactam : 15/15 mg/ml         |  | 4801 |
|  |  | Furosemide : 10 mg/ml<br>Tacrolimus : 1000 µg/ml                    |  | 479  |
|  |  | Furosemide : 3 mg/ml<br>Tedizolid phosphate : 0.8 mg/ml             |  | 3827 |
|  |  | Furosemide : 10 mg/ml<br>Temocilline : 83.33 mg/ml                  |  | 2231 |
|  |  | Furosemide : 10 mg/ml<br>Thiopental sodium : 25 mg/ml               |  | 314  |

|  |  |                                                             |  |      |
|--|--|-------------------------------------------------------------|--|------|
|  |  | Furosemide : 10 mg/ml<br>Thiopental sodium : 60 mg/ml       |  | 3823 |
|  |  | Furosemide : 10 mg/ml<br>Thiopental sodium : 25 mg/ml       |  | 3767 |
|  |  | Furosemide<br>Tirofiban                                     |  | 1512 |
|  |  | Furosemide : 1 mg/ml<br>Tobramycin sulfate : 8 mg/ml        |  | 1232 |
|  |  | Furosemide<br>Urapidil                                      |  | 3465 |
|  |  | Furosemide : 10 mg/ml<br>Urapidil : 5 mg/ml                 |  | 3823 |
|  |  | Furosemide : 10 mg/ml<br>Urapidil : 5 mg/ml                 |  | 3463 |
|  |  | Furosemide : 10 mg/ml<br>Vasopressin : 1 UI/ml              |  | 4570 |
|  |  | Furosemide : 1 mg/ml<br>Vasopressin : 1 UI/ml               |  | 4570 |
|  |  | Furosemide : 10 mg/ml<br>Vecuronium bromide : 1 mg/ml       |  | 314  |
|  |  | Furosemide : 1 mg/ml<br>Verapamil hydrochloride : 0.5 mg/ml |  | 1232 |
|  |  | Furosemide : 10 mg/ml<br>Vinblastine sulfate : 1 mg/ml      |  | 763  |
|  |  | Furosemide : 10 mg/ml<br>Vincristine sulfate : 1 mg/ml      |  | 763  |
|  |  | Furosemide : 3 mg/ml<br>Vinorelbine tartrate : 1 mg/ml      |  | 84   |



## método de inyección



## Bibliografía

|    | Tipo      | Publicación                                                                                                                                                                                                                 |
|----|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3  | periódico | Trissel LA, Martinez JF.<br>Compatibility of amifostine with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 2208-2212.                                                         |
| 49 | periódico | Trissel LA, Martinez JF.<br>Compatibility of granisetron hydrochloride with selected alkaline drugs.<br>Am J Health-Syst Pharm 1995 ; 52: 208.                                                                              |
| 57 | periódico | Mayron D, Gennaro AR.<br>Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.<br>Am J Health-Syst Pharm 1996 ; 53: 294-304. |

|     |           |                                                                                                                                                                                                                                        |
|-----|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 59  | periódico | Trissel LA, Gilbert DL, Martinez JF, Kim MC.<br>Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 2192-2196.                                |
| 62  | periódico | Pugh CB, Pabis DJ, Rodriguez C.<br>Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 123-125.                         |
| 63  | periódico | Marquardt Ed, Lam SSY.<br>Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1994 ; 51: 811-812.                                                                       |
| 73  | periódico | Lor E, Takagi J.<br>Visual compatibility of foscarnet with other injectable drugs.<br>Am J Hosp Pharm 1990 ; 47: 157-159.                                                                                                              |
| 81  | periódico | Trissel LA, Martinez JF.<br>Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1994 ; 51: 672-678.                                                         |
| 84  | periódico | Trissel LA, Martinez JF.<br>Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1994 ; 51: 495-499.              |
| 87  | periódico | Lee DKT, Lee A, Wang DP.<br>Compatibility of cefoperazone sodium and furosemide in 5% dextrose injection.<br>Am J Hosp Pharm 1991 ; 48: 108-110.                                                                                       |
| 89  | periódico | Zeisler J, Alagna C.<br>Incompatibility of labetalol hydrochloride and furosemide.<br>Am J Hosp Pharm 1993 ; 50: 2521-2522.                                                                                                            |
| 91  | periódico | Lober CA, Dollard PA.<br>Visual compatibility of gallium nitrate with selected drugs during Y-site injection.<br>Am J Hosp Pharm 1993 ; 50: 1208-1210.                                                                                 |
| 93  | periódico | Hutchings SR, Rusho WJ, Tyler LS.<br>Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.<br>Am J Health-Syst Pharm 1996 ; 53: 2185-2188.                                                              |
| 99  | periódico | Trissel LA, Martinez JF.<br>Compatibility of aztreonam with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 1086-1090.                                                                     |
| 169 | periódico | Trissel LA, Martinez JF.<br>Physical compatibility of melphalan with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1993 ; 50: 2359-2363.                                                                   |
| 176 | periódico | Mantong ML, Marquardt ED.<br>Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.<br>Am J Health-Syst Pharm 1995 ; 52: 2567-2568.                                                    |
| 186 | periódico | Swart EL, Mooren RAG, Van Loenen AC.<br>Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 2020-2022.                             |
| 191 | periódico | Riley CM.<br>Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection.<br>Am J Hosp Pharm 1988 ; 45: 2079-2091. |
| 198 | periódico | Gayed AA, Kheshary PR, Hinkle RL.<br>Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.<br>Am J Health-Syst Pharm 1995 ; 52: 516-520.                                |

|     |           |                                                                                                                                                                                                                                        |
|-----|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 215 | periódico | Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.<br>Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.<br>Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 242 | periódico | Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M.<br>Stability of amiodarone hydrochloride in admixtures with other injectable drugs.<br>Am J Hosp Pharm 1986 ; 43: 917-921.                                                         |
| 244 | periódico | Trissel LA, Martinez JF.<br>Compatibility of filgrastim with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1994 ; 51: 1907-1913.                                                                           |
| 248 | periódico | Trissel LA, Martinez JF.<br>Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1993 ; 50: 300-304.                                                       |
| 249 | periódico | Trissel LA, Martinez JF.<br>Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1996 ; 53: 1041-1045.                                                        |
| 251 | periódico | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 2708-2713.                |
| 253 | periódico | Trissel LA, Chandler SW, Folstad JT.<br>Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1990 ; 47: 2525-2528.                                                              |
| 266 | periódico | Patel PR.<br>Compatibility of meropenem with commonly used injectable drugs.<br>Am J Health-Syst Pharm 1996 ; 53: 2853-2855.                                                                                                           |
| 288 | periódico | Cervenka P, Dejong DJ, Butler BL, Monzingo MD.<br>Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.<br>Hosp Pharm 1992 ; 27: 957-958,961-962.            |
| 289 | periódico | Jim LK.<br>Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.<br>Ann Pharmacotherapy 1993 ; 27: 704-707.                                                                                               |
| 299 | periódico | Trissel LA, Martinez JF, Gilbert DL.<br>Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1735-1741.                                            |
| 300 | periódico | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1287-1292.                                      |
| 301 | periódico | Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.<br>Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1295-1300.   |
| 307 | periódico | Trissel LA, Martinez JF.<br>Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1994 ; 51: 1792-1799.                                                                   |
| 314 | periódico | Chiu MF, Schwartz ML.<br>Visual compatibility of injectable drugs used in the intensive care unit.<br>Am J Health-Syst Pharm 1997 ; 54: 64-65.                                                                                         |
| 316 | periódico | Veltri M, Lee CKK.<br>Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.<br>Am J Health-Syst Pharm 1996 ; 53: 2611-2613.                                                                         |

|     |           |                                                                                                                                                                                                                                       |
|-----|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 334 | periódico | Trissel LA, Tramonte SM, Grilley BJ.<br>Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 988-992.                                               |
| 335 | periódico | Trissel LA, Bready BB, Kwan JW, Santiago NM.<br>Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1992 ; 49: 402-406.   |
| 367 | periódico | Thompson DF, Allen LV, Desai SR, Rao PS.<br>Compatibility of furosemide with aminoglycoside admixtures.<br>Am J Hosp Pharm 1985 ; 42: 116-119.                                                                                        |
| 397 | periódico | Fong PA, Ward J.<br>Visual compatibility of intravenous famotidine with selected drugs.<br>Am J Hosp Pharm 1989 ; 46: 125-126.                                                                                                        |
| 398 | periódico | Jay GT, Fanikos J, Souney PF.<br>Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.<br>Am J Hosp Pharm 1988 ; 45: 1556-1557.                                          |
| 467 | periódico | Ishisaka DY, van Vleet J, Marquardt E.<br>Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion.<br>Am J Hosp Pharm 1991 ; 48: 2442-2443.                                        |
| 479 | periódico | Min DI, Brown T, HWang GC.<br>Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1992 ; 49: 2964-2966.                                                                 |
| 491 | periódico | Turowski RC, Durthaler JM.<br>Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 2181-2184.                                                        |
| 492 | periódico | Trissel LA, Parks NPT, Santiago NM.<br>Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 | periódico | Lor E, Sheybani T, Takagi J.<br>Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1991 ; 48: 744-746.                                                |
| 523 | periódico | Thompson DF, Thompson GD.<br>Visual compatibility of esmolol hydrochloride and furosemide in 5% dextrose or 0.9% sodium chloride injections.<br>Am J Hosp Pharm 1987 ; 44: 2740.                                                      |
| 763 | periódico | Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.<br>Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.<br>Cancer Treat Rep 1985 ; 69: 1325-1326.                 |
| 789 | periódico | Garner SS, Wiest DB.<br>Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system.<br>Am J Hosp Pharm 1990 ; 47: 604-606.                                                                       |
| 796 | periódico | Asker AF, Ferdous AJ.<br>Photodegradation of furosemide solutions.<br>PDA J Pharm Sci Technol 1996 ; 50: 158-162.                                                                                                                     |
| 805 | periódico | Oskroba DM, Leissing NC, Trissel LA.<br>An automated process for determining the physical compatibility of drugs.<br>Hosp Pharm 1997 ; 32: 1013-1020.                                                                                 |
| 905 | periódico | Trissel LA, Martinez JF.<br>Screening teniposide for Y-site physical incompatibilities.<br>Hosp Pharm 1994 ; 29: 1010-1017.                                                                                                           |



|      |           |                                                                                                                                                                                                                                          |
|------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 921  | periódico | Trissel LA, Gilbert DL, Martinez JF.<br>Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.<br>Hosp Pharm 1998 ; 33: 284-292.              |
| 939  | periódico | Gilbar PJ, Groves CF.<br>Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.<br>Aust J Hosp Pharm 1994 ; 24: 167-170.                              |
| 1041 | periódico | Hasegawa GR, Eder JF.<br>Visual compatibility of dobutamine hydrochloride with other injectable drugs.<br>Am J Hosp Pharm 1984 ; 41: 949-951.                                                                                            |
| 1049 | periódico | Klamerus KJ, Ueda CT, Newton DW.<br>Stability of nitroglycerin in intravenous admixtures.<br>Am J Hosp Pharm 1984 ; 41: 303-305.                                                                                                         |
| 1057 | periódico | Cutie MR.<br>Compatibility of verapamil hydrochloride injection with commonly used additives.<br>Am J Hosp Pharm 1983 ; 40: 1205-1207.                                                                                                   |
| 1058 | periódico | Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.<br>Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.<br>Am J Hosp Pharm 1983 ; 40: 1690-1691.                 |
| 1072 | periódico | Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.<br>Compatibility of levofloxacin with 34 medications during simulated Y-site administration.<br>Am J Health-Syst Pharm 1999 ; 56: 1458-1459.                                        |
| 1088 | periódico | Johnston A, McKenzie MA, Krasnow SH, Hood MA, Cohen MH.<br>Drug trapping in intravenous infusion side arms.<br>JAMA 1984 ; 252: 2392.                                                                                                    |
| 1201 | periódico | Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.<br>Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.<br>Am J Hosp Pharm 1981 ; 38: 1919-1922.                                         |
| 1228 | periódico | Allen LV, Stiles ML.<br>Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.<br>Am J Hosp Pharm 1981 ; 38: 380-381.                                                                       |
| 1232 | periódico | Beatson C, Taylor A.<br>A physical compatibility study of furosemide & flucloxacillin injections.<br>Br J Pharm Pract 1987 ; 9: 223-226, 236.                                                                                            |
| 1289 | periódico | Hecq JD, Evrard JM, Gillet P, Grosdent N.<br>Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l'héparine sodique en perfusion continue.<br>Pharmakon 1998 ; 116: 145-148. |
| 1338 | periódico | Baptista RJ, Dumas GJ, Bistran BR, Condella F, Blackburn GL.<br>Compatibility of total nutrient admixtures and secondary cardiovascular medications.<br>Am J Hosp Pharm 1985 ; 42: 777-778.                                              |
| 1410 | periódico | Trissel LA, Martinez JF, Simmons M.<br>Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.<br>J Am Pharm Assoc 1999 ; 39: 141-145.                                                               |
| 1415 | periódico | Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.<br>Compatibility of medications with 3-in-1 parenteral nutrition admixtures.<br>JPEN 1999 ; 23: 67-74.                                                      |
| 1423 | periódico | Trissel LA, Martinez JF, Gilbert DL.<br>Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection.<br>J Am Pharm Assoc 1999 ; 39: 514-518.                                                    |

|      |             |                                                                                                                                                                                                                   |
|------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1496 | periódico   | Trissel LA, Martinez JF, Gilbert DL.<br>Screening cladribine for Y-site physical compatibility with selected drugs.<br>Hosp Pharm 1996 ; 31: 1425-1428.                                                           |
| 1506 | periódico   | Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.<br>Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.<br>EJHP 2015 ;22:107-112.               |
| 1508 | periódico   | Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.<br>Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.<br>EJHP 2015 ;22:123-124.                           |
| 1512 | Laboratorio | Tirofiban (Aggrastat®) - Summary of Product Characteristics<br>Beacon Pharmaceuticals Ltd 2015                                                                                                                    |
| 1603 | periódico   | Bergquist PA, Manas D, Hunke WA, Reed RA.<br>Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.<br>Am J Health-Syst Pharm 2001 ; 58: 1218-1223.      |
| 1611 | periódico   | Chalmers JR, Bobek MB, Militello MA.<br>Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.<br>Am J Health-Syst Pharm 2001 ; 58: 504-506.                                  |
| 1625 | periódico   | Trissel LA, Saenz C, Williams YW, Ingram D.<br>Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.<br>Int J Pharm Compound 2001 ; 5: 314-321.                  |
| 1662 | periódico   | Trissel LA, Saenz CA, Ingram DS, Ogundele AB.<br>Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.<br>J Oncol Pharm Practice 2002 ; 8: 33-37.                       |
| 1680 | periódico   | Donnelly RF.<br>Chemical stability of furosemide in minibags and polypropylene syringes.<br>Int J Pharm Compound 2002 ; 6: 468-470.                                                                               |
| 1703 | periódico   | Schuster F, Bernard R.<br>Kompatibilität von enalaprilat i.v. mit ausgewählten Arzneimitteln.<br>Krankenhauspharmazie 1995 ; 16: 101-103.                                                                         |
| 1712 | periódico   | Trissel LA, Saenz CA.<br>Compatibility screening of Precedex during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2002 ; 6: 230-233.                                                  |
| 1713 | periódico   | Trissel LA, Saenz CA.<br>Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2002 ; 6: 311-315.                                               |
| 1721 | periódico   | Trissel LA, Williams KY, Baker MB.<br>Compatibility screening of Hextend during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2001 ; 5: 69-72.                                        |
| 1754 | periódico   | Trissel LA, Gilbert DL, Wolkin AC.<br>Compatibility of docetaxel with selected drugs during simulated Y-site administration.<br>Int J Pharm Compound 1999 ; 3: 241-244.                                           |
| 1759 | periódico   | Servais H, Tulkens PM.<br>Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.<br>Antimicrob Agents Chemother 2001 ; 45: 2643-2647.                         |
| 1800 | periódico   | Voytilla KL, Tyler LS, Rusho WJ.<br>Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.<br>Am J Health-Syst Pharm 2002 ; 59: 853-855.                              |
| 1803 | periódico   | Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.<br>Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2003 ; 60: 80-85.              |
| 1855 | periódico   | Carla-Broch S, Esteve-Romero J, Garcia-Alvarez-Coque MC.<br>Furosemide assay in pharmaceuticals by Micellar liquid chromatography: study of the stability of the drug.<br>J Pharm Biomed Anal 2000 ; 23: 803-817. |

|      |           |                                                                                                                                                                                                                                                                                                                                                                           |
|------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1888 | periódico | Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A.<br>Compatibility study of midazolam.<br>Ziekenhuisfarmacie 1986 ; 2: 45-48.                                                                                                                                                                                                                            |
| 1902 | periódico | Walker SE, Wyllie A, Law S.<br>Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.<br>Can J Hosp Pharm 2004 ; 57, 2: 90-96.                                                                                                                                                                                          |
| 1925 | periódico | Trissel LA , Williams KY, Gilbert DL.<br>Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.<br>J Am Pharm Assoc 2000 ; 40: 515-519.                                                                                                                                                           |
| 1963 | periódico | Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS.<br>Compatibility of argatroban with selected cardiovascular agents.<br>Am J Health-Syst Pharm 2004 ; 61: 2415-2418.                                                                                                                                                                                            |
| 1982 | periódico | Trissel LA, Ogundele AB.<br>Compatibility of anidulafungin with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2005 ; 62: 834-837.                                                                                                                                                                                                         |
| 2087 | periódico | Ferreira E, Forest JM, Hildgen P.<br>Compatibility of dimenhydrinate injectable by Y administration.<br>Pharmactuel 2004 ; 37: 17-20.                                                                                                                                                                                                                                     |
| 2090 | periódico | Pere H, Chasse V, Forest JM, Hildgen P.<br>Compatibility of injectable pantoprazole in Y-site administration.<br>Pharmactuel 2004 ; 37: 193-196.                                                                                                                                                                                                                          |
| 2108 | periódico | Trusley C, Kupiec TC, Trissel LA.<br>Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.<br>Int J Pharm Compound 2006 ; 10: 230-232.                                                                                                                                                                                        |
| 2109 | periódico | Pelletier E, Forest JM, Hildgen P.<br>Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels.<br>Pharmactuel 2006 ; 39: 71-75.                                                                                                                                                                                       |
| 2116 | periódico | Faria CE, Fiumara K, Patel N, Tran DC.<br>Visual compatibility of furosemide with phenylephrine and vasopressine.<br>Am J Health-Syst Pharm 2006 ; 63: 906-908.                                                                                                                                                                                                           |
| 2141 | periódico | Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.<br>Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.<br>J Antimicrob Chemother 2003 ; 51: 651-658. |
| 2205 | periódico | Negro S, Rendon AL, Azuara ML, S'ñchez Y, Fern'ndez-Carballido A, Barcia E.<br>Compatibility and stability of furosemide and dexamethasone combined in infusion solutions.<br>Arzneimittel Forschung 2006 ; 56, 10: 714-720.                                                                                                                                              |
| 2231 | periódico | de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.<br>Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.<br>J Antimicrob Chemother 2008 ; 61, 2: 382-388.                     |
| 2233 | periódico | Condie C.K, Tyler L.S, Barker B, Canann D.M.<br>Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery<br>Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.                                                                                                                                                                    |
| 2247 | periódico | Chan P, Heatherly K, Kupiec T.C, Trissel L.A.<br>Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.<br>Int J Pharm Compound 2008 ; 12, 3: 276-278.                                                                                                                                                                 |
| 2262 | periódico | Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.<br>Compatibility of doripenem with other drugs during simulated Y-site administration<br>Am J Health-Syst Pharm 2008 ; 65: 1261-1265.                                                                                                                          |

|      |             |                                                                                                                                                                                                                                                        |
|------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2269 | periódico   | Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.<br>Compatibility of ceftobiprole medocartil with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.                 |
| 2346 | periódico   | Newland A.M, Mauro V.F, Alexander K.S.<br>Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents<br>Am J Health-Syst Pharm 2009 ; 66: 986-987.                                                                    |
| 3012 | periódico   | Sullivan T, Forrest J.M, Leclair G.<br>Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration<br>Hosp Pharm 2015 ; 50, 3: 214-220.                                                                 |
| 3134 | periódico   | Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM.<br>Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.<br>Enferm Intensiva 2010 ; 21: 96-103.                         |
| 3152 | periódico   | Kumar A, Mann HJ.<br>Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2010 ; 67: 1640-1644.                                                        |
| 3176 | póster      | Humbert Delaloye V, Berger M, Voirol P, Pannatier A.<br>Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté.<br>16èmes JFSPH, Sion, 18-19 novembre 2010                                                          |
| 3184 | Laboratorio | Hyaluronidase (Hyalase®) - Summary of Product characteristics.                                                                                                                                                                                         |
| 3201 | periódico   | ORPHEUM Pharmaceuticals 2005<br>Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit.<br>J Pediatr Pharmacol Ther 2006 ; 11:233-236.                                              |
| 3210 | periódico   | Jasti Bhaskara R, Saraf Poonam.<br>Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.<br>Int J Pharm Compound 2011 ; 15, 3: 259-261.                                                               |
| 3212 | periódico   | Ribas Nicolau, B.; Pérez Juan, E.; Amor's Cerdà, S.M.; Arévalo Rubert, M.J.; Maqueda Palau, M.<br>Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos.<br>Enferm Intensiva 2011 ; 22:78-82. |
| 3216 | periódico   | Legrís ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.<br>Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.<br>Pharmactuel 2011 ; 44, 1 : 14-18                                              |
| 3249 | periódico   | Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.<br>Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2011 ; 68: 2163-2169.         |
| 3254 | periódico   | Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.<br>Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration<br>Am J Health-Syst Pharm 2011 ; 68: 2265-2270.                                   |
| 3294 | periódico   | Humbert-Delaloye V, Berger M, Voirol P, Pannatier A.<br>In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs<br>EJHP 2012 ; 19: 57-64.                                                                      |
| 3372 | periódico   | Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.<br>Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.<br>Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.                                    |
| 3385 | periódico   | Raverdi V, Ampe E, Hecq JD, Tulkens PM.<br>Stability and compatibility of vancomycin for administration by continuous infusion.<br>J Antimicrob Chemother 2013 ; 68: 1179-1182.                                                                        |
| 3408 | periódico   | Tollec S, Touzin K, Pelletier E, Forest J.M.<br>Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels.<br>Pharmactuel 2013 ; 46, 1 : 16-21.                                                    |

|      |             |                                                                                                                                                                                                                                                           |
|------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3463 | periódico   | Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R.<br>Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad.<br>Nursing 2011 ; 29 :62-6                             |
| 3464 | periódico   | Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau.<br>Compatibilidad física de la amiodarona en perfusión continua<br>Enferm Clin 2011 21:25-29.                                        |
| 3465 | periódico   | E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?.<br>Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.<br>Enferm Intensiva 2010 ;21:96-103.                         |
| 3466 | periódico   | B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau.<br>Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos<br>Enferm Intensiva 2011 ;22:78-82.          |
| 3490 | periódico   | Elwell R.J, Spencer A.P, Barnes J.F, Wynn J.E, Jones C.E.<br>Stability of furosemide in human albumin solution.<br>Ann Pharmacotherapy 2002 ; 36: 423-426.                                                                                                |
| 3531 | Laboratorio | Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics<br>Wockhardt 2014                                                                                                                                                            |
| 3564 | Laboratorio | Rocuronium B Braun - Résumé des caractéristiques du produit.<br>B Braun 2012                                                                                                                                                                              |
| 3607 | Laboratorio | Esmolol hydrochloride for injection - Summary of Product Characteristics<br>AOP Orphan Pharmaceuticals AG 2013                                                                                                                                            |
| 3612 | Laboratorio | Doxapram (Dopram) - Summary of Product Characteristics<br>Amdipharm Mercury Company 2012                                                                                                                                                                  |
| 3614 | Laboratorio | Nicardipine Injection - Summary of Product Characteristics<br>American Regent Inc 2013                                                                                                                                                                    |
| 3617 | Laboratorio | Hyaluronidase (Hyalase®) - Summary of Product Characteristics<br>Wockhardt 2011                                                                                                                                                                           |
| 3639 | Laboratorio | Furosemide - Summary of Product Characteristics<br>Wockhardt 2013                                                                                                                                                                                         |
| 3646 | Laboratorio | Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit<br>Sanofi Aventis France 2013                                                                                                                                            |
| 3664 | periódico   | Zhao B, Sun W.<br>Incompatibility of esmolol hydrochloride and furosemide in a central venous access port<br>Am J Health-Syst Pharm 2014 ; 71:901-902.                                                                                                    |
| 3718 | Laboratorio | Conivaptan (Vaprisol®) - Summary of Product Characteristics<br>Bayer Healthcare Corporation 2012                                                                                                                                                          |
| 3728 | periódico   | Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.<br>Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2014 ; 71: 1288-1291.                                          |
| 3766 | periódico   | Forrest J.M, Hildgen P.<br>Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels<br>Pharmactuel 2014 ; 47, 3 : 161-165.                                                                           |
| 3767 | periódico   | Legris M.E, Lavoie A, Forrest J.M, Hildgen P.<br>Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.<br>Pharmactuel 2014 ; 47, 3 : 167-172.                                       |
| 3781 | periódico   | Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A<br>Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide.<br>EJHP 2015 ;22:1 56-58 |

|      |             |                                                                                                                                                                                                                                                           |
|------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3821 | periódico   | Cies J.J, Moore W.S, Chopra A, Lu G, Mason R.W.<br>Stability of furosemide and chlorothiazide stored in syringes.<br>Am J Health-Syst Pharm 2015 ; 72:2182-2188                                                                                           |
| 3823 | periódico   | Juan E.P, Palau M.M, Cerdá S.A, Rubert M.A, Nicolau B.R.<br>Compatibilité physique de médicaments administrés dans l'unité de soins intensifs<br><br>Pharmactuel 2015 ; 48, 3 : 146-152.                                                                  |
| 3824 | periódico   | Boudi S, Roy H, Forest JM, Leclair G.<br>Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.<br>Pharmactuel 2023 2023;56,3:91-98                       |
| 3827 | póster      | Ghazi I.M, Hamada Y, Nicolau D.P.<br>Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.<br>ASHP Midyear 2015                                                                                           |
| 3828 | póster      | Thabit A.K, Hamada Y, Nicolau D.P.<br>Ceftazolin/tazobactam physical compatibility during simulated Y-site administration.<br>ASHP Midyear 2015                                                                                                           |
| 3829 | póster      | So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.<br>Compatibility of isavanazonium sulfate during simulated Y-site administration.<br>ASHP Midyear 2015                                                                                                    |
| 3934 | Laboratorio | Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit<br>GlaxoSmithKline Laboratoire 2016                                                                                                                                                   |
| 3941 | Laboratorio | Nicardipine - Summary of Product Characteristics<br>Concordia International 2017                                                                                                                                                                          |
| 3948 | periódico   | Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P .<br>Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.<br>JPEN 2012 ;30. 416-424.                                                                          |
| 3964 | periódico   | Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.<br>Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.<br>Pharmactuel 2017 ; 50,1 : 27-33.                                                                            |
| 3967 | periódico   | Staven V, Herra I, Wang S, Grönlund I, Tho I.<br>Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents.<br>J Pharm Pharmacol 2017 ;69,7:448-462                                |
| 3976 | periódico   | Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.<br>Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218 |
| 3985 | póster      | Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M.<br>Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro.<br>Hopipharm Congress 2017 - Nancy 2017              |
| 4055 | periódico   | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.<br>Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 , 75, 1:36-44                                   |
| 4130 | periódico   | Koller AK, Krebs S, Dörje F.<br>Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzten Arzneimitteln auf Intensivstationen.<br>Pharmaceutics 2021 , 13, 21.                                                                               |
| 4145 | periódico   | Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.<br>Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 ;75,14:1048-1056                                            |
| 4154 | Laboratorio | Bleomycin sulfate- Summary of Product Characteristics<br>Accord Health Care 2018                                                                                                                                                                          |



|      |           |                                                                                                                                                                                                                                                      |
|------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4319 | periódico | Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.<br>Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.<br>Hosp Pharm 2020 ; 55, 5: 332-337.                                                           |
| 4332 | póster    | Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI)<br>Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI).<br>JFSPH 2019 2019               |
| 4341 | periódico | Van der Schaar JAJ, Grouls R, Franssen EJF, Crul M.<br>Stability of Furosemide 5 mg/mL in Polypropylene Syringes.<br>Int J Pharm Compound 2019 ;23,5:414-417                                                                                         |
| 4370 | periódico | Staven V, Wang S, Gronlie I, Tho I.<br>Physical stability of an all-in one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs<br>EJHP 2018 2018;0:1-7                                                      |
| 4389 | periódico | Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.<br>Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisentan et la kétamine.<br>Pharmactuel 2019 ;52,4:206-213 |
| 4419 | periódico | Holt R.J, Siegert S.W.K, Krishna A.<br>Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.<br>J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.                                                |
| 4426 | periódico | Watrobska-Swietlikowska D, Pietka M, Stanislaw Klek S.<br>Evaluation of Y-site compatibility of home total parenteral nutrition and intravenous loop diuretics.<br>Medicine 2019 98:21(e15747)                                                       |
| 4433 | periódico | Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.<br>Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications<br>Clin Ther 2020 ; 42, 3: 475-485.                                                     |
| 4434 | periódico | Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.<br>Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.<br>Clin Ther 2019 ; 41, 10: 2162-2170.                       |
| 4491 | periódico | De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A.<br>Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.<br>Eur J Pediatr 2020       |
| 4506 | periódico | Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C.<br>Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration.<br>Am J Health-Syst Pharm 2020 ;77,23:1938-1940.                 |
| 4507 | periódico | Ross E, Salinas A, Petty K, Her C, Carpenter J.<br>Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.<br>Am J Health-Syst Pharm 2020 ;77,23:1980-1985                                                |
| 4515 | periódico | Tomczak S, Stawny M, Jelinska A.<br>Co-Administration of Drugs and Parenteral Nutrition: In Vitro Compatibility Studies of Loop Diuretics for Safer Clinical Practice.<br>Pharmaceutics 2020                                                         |
| 4521 | periódico | Polo C, D'Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.<br>Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.<br>Pharmaceutical Technology in Hospital Pharmacy 2020                              |
| 4524 | póster    | Stucki C, Sautter A-M, Bonnabry P.<br>Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology.<br>ESCP Symposium, Geneva, Switzerland 2009                                                                             |
| 4528 | periódico | Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.<br>Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.<br>Int J Pharm Compound 2021 ;25,1:52-61                                       |


|      |             |                                                                                                                                                                                                                                                                                                              |
|------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4570 | periódico   | Greenhill K, Hornsby E, Gorman G.<br>Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients.<br>Pharmaceuticals 2019                                                             |
| 4571 | Laboratorio | Levosimendan (Simdax 2.5 mg/ml) - Summary of Product Characteristics<br>Orion Pharma 2010                                                                                                                                                                                                                    |
| 4603 | periódico   | Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.<br>Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.<br>Hosp Pharm 2021 ; 56, 4: 228-234.                                                              |
| 4605 | periódico   | Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P.<br>Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility.<br>Ann Allergy 2012 ; 2:28.                                                                                                          |
| 4651 | periódico   | De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A.<br>Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.<br>Eur J Pedia 2021 ;180,1169–1176.                                               |
| 4654 | póster      | Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.<br>Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.<br>Communication personnelle 2021                                                                                      |
| 4698 | periódico   | Ayari G, Huart E, Vigneron J, Demoré B.<br>Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.<br>Pharmaceutical Technology in Hospital Pharmacy 2022 ; 7(1): 20220002                                        |
| 4724 | periódico   | Maktabi B, Howard MS, Baki G, Churchwell MD<br>Intravenous Physical Compatibility of Heparin Sodium and Furosemide.<br>Int J Pharm Compound 2022 ;26,6:522-526                                                                                                                                               |
| 4742 | periódico   | Macoviciuc M, Nguyen C, Forest J-M, Leclair G.<br>Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y.<br>Pharmactuel 2022 ; 55, 4: 247-255.                                                                                                    |
| 4768 | periódico   | Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H.<br>Y-site injection physical compatibility of remdesivir with select intravenous drugs used in palliative care and for treating coronavirus disease 2019.<br>Journal of Nippon Medical school 2023                           |
| 4801 | periódico   | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.<br>Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2024 ;51,1:                                                                             |
| 4837 | periódico   | De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T.<br>Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.<br>Eur J Clin Pharmacol 2024 ; 80:1079–1087.                   |
| 4845 | periódico   | De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T.<br>The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings.<br>Pharmaceutics 2024 ;1 6, 419.                                                               |
| 4867 | póster      | Dazan D, Aït Taleb S, Laroyenne N, Hamam Y, Conreur L, Paoli-Lombardo R, Primas N, Lamy E, Castera-Ducros C, Curti C et al.<br>Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie.<br>CSH (SNPHPU) Congress sept 2024 2024 |
| 4987 | Laboratorio | MILRINONE TILLOMED 1 mg/mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit.<br>TILLOMED PHARMA GMBH 2024                                                                                                                                                                        |

|      |             |                                                                                                                                  |
|------|-------------|----------------------------------------------------------------------------------------------------------------------------------|
| 5093 | Laboratorio | FUROSEMIDE ACCORD 20 mg/2 ml, solution injectable - Résumé des caractéristiques du produit.<br>ACCORD HEALTHCARE FRANCE SAS 2024 |
|------|-------------|----------------------------------------------------------------------------------------------------------------------------------|

# Stabilis



## Furosemide



### La estabilidad de las preparaciones farmacéuticas

|  | 500 mg Ipca Laboratoire® | Jarabe simple >> 100 mL                                                                            | 2-8°C        |  | 30  |  |  | 4044 |
|--|--------------------------|----------------------------------------------------------------------------------------------------|--------------|--|-----|--|--|------|
|  | 500 mg Artenium®         | Jarabe simple >> 100 mL                                                                            | 2-8°C        |  | 30  |  |  | 4044 |
|  | 500 mg Sanofi®           | Jarabe simple >> 100 mL                                                                            | 2-8°C        |  | 30  |  |  | 4044 |
|  | 500 mg Ipca Laboratoire® | Jarabe simple >> 100 mL                                                                            | 21-25°C      |  | 30  |  |  | 4044 |
|  | 500 mg Artenium®         | Jarabe simple >> 100 mL                                                                            | 21-25°C      |  | 30  |  |  | 4044 |
|  | 500 mg Sanofi®           | Jarabe simple >> 100 mL                                                                            | 21-25°C      |  | 30  |  |  | 4044 |
|  | 200 mg ® = ?             | metilparabeno 100 mg<br>NaOH 24 mg<br>Sacarina sódica 100 mg<br>Agua para inyección >> 100 mL      | 22-28°C      |  | 270 |  |  | 4060 |
|  | 200 mg ® = ?             | metilparabeno 100 mg<br>NaH2PO4 1500 mg<br>Sacarina sódica 100 mg<br>Agua para inyección >> 100 mL | 22-28°C      |  | 270 |  |  | 4060 |
|  | 200 mg ® = ?             | metilparabeno 100 mg<br>NaOH 24 mg<br>Sacarina sódica 100 mg<br>Agua para inyección >> 100 mL      | 40 +/- 0,5°C |  | 270 |  |  | 4060 |
|  | 200 mg ® = ?             | metilparabeno 100 mg<br>Na2HPO4 1500 mg<br>Sacarina sódica 100 mg<br>Agua para inyección >> 100 mL | 40 +/- 0,5°C |  | 30  |  |  | 4060 |
|  | 964 mg ® = ?             | SyrSpend SF Alka® >> 100 mL                                                                        | 2-8°C        |  | 14  |  |  | 3810 |



## Bibliografía

|      | Tipo      | Publicación                                                                                                                                                                                        |
|------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3810 | periódico | Geiger C M, Sorenson B, Whaley P.<br>Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF.<br>Int J Pharm Compound 2015 ; 19, 5 : 420-427.                       |
| 4044 | periódico | Alfred-Ugbendo D, Zdoryk O.A, Georgiyants V.A.<br>Quality assessment and stability study of compounded furosemide syrup.<br>Pharm Sci Communications 2017 ;9:5:28-35                               |
| 4060 | periódico | Zahalka L, Klovzova S, Matysova L, Sklupalova Z, Solich P.<br>Furosemide ethanol-free oral solutions for paediatric use : formulation, HPLC method and stability study.<br>EJHP 2018 ;25,3:144-149 |



# Diccionario

|  |                                            |  |                                     |
|--|--------------------------------------------|--|-------------------------------------|
|  | Diurético                                  |  | Injectables                         |
|  | Nombre comercial                           |  | Estabilidad en solución             |
|  | Envase                                     |  | Molécula                            |
|  | Concentración                              |  | Temperatura                         |
|  | Conservación                               |  | Duración de la estabilidad          |
|  | biosimilar                                 |  | datos contradictorios               |
|  | Bibliografía                               |  | Cloruro de polivinilo               |
|  | Cloruro de sodio 0,9%                      |  | A cubierto de la luz                |
|  | Día                                        |  | Luz                                 |
|  | jeringa polipropileno                      |  | Hora                                |
|  | Glucosa 5%                                 |  | Estabilidad en mezcla               |
|  | Solvente                                   |  | Molécula                            |
|  | Vidrio                                     |  | Ninguno                             |
|  | Polipropileno                              |  | No precisado                        |
|  | Factores que influyen sobre la estabilidad |  | Provoque                            |
|  | Degradación                                |  | Precipitación                       |
|  | Nutrición parenteral (libre de lípidos)    |  | Compatibilidades                    |
|  | Compatible                                 |  | Precipitación inmediata             |
|  | Incompatible                               |  | Turbidez inmediata                  |
|  | Turbidez en 4 horas                        |  | Precipitación después de 4 horas.   |
|  | Incompatibilidad no especificada           |  | RL Ringer lactato                   |
|  | NaCl 0,9% + bacteriostático                |  | Turbidez en una hora                |
|  | Precipitación después de 5 horas.          |  | Modificación de pH > 1 unidad de pH |
|  | Inestabilidad química                      |  | Nutrición parenteral (con lípidos)  |
|  | NaHCO3                                     |  | Precipitación después de 1 hora     |
|  | Turbidez en 24 horas                       |  | Precipitación después de 15 minutos |
|  | Agua para preparación inyectable           |  | Producción de burbujas de gas.      |
|  | Precipitación después de 2 horas.          |  | específico disolvente               |
|  | Precipitación después de 7 horas.          |  | método de inyección                 |
|  | Intravenoso                                |  | Perfusión intravenosa               |



|                                                                                                                                     |                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|  Perfusión continua                                 |  Intramuscular          |
|  Subcutánea                                        |  Perfusión SC continua |
|  Bibliografía                                      |  Solución Oral         |
|  La estabilidad de las preparaciones farmacéuticas |  Orígenes              |
|  Excipiente                                        |  Polvo                 |
|  Tabletas                                          |  Botella de plástico   |
|  No precisada                                      |  Diccionario           |